203 related articles for article (PubMed ID: 27590350)
1. Multi-focal control of mitochondrial gene expression by oncogenic MYC provides potential therapeutic targets in cancer.
Oran AR; Adams CM; Zhang XY; Gennaro VJ; Pfeiffer HK; Mellert HS; Seidel HE; Mascioli K; Kaplan J; Gaballa MR; Shen C; Rigoutsos I; King MP; Cotney JL; Arnold JJ; Sharma SD; Martinez-Outschoorn UE; Vakoc CR; Chodosh LA; Thompson JE; Bradner JE; Cameron CE; Shadel GS; Eischen CM; McMahon SB
Oncotarget; 2016 Nov; 7(45):72395-72414. PubMed ID: 27590350
[TBL] [Abstract][Full Text] [Related]
2. The mitochondrial translation machinery as a therapeutic target in Myc-driven lymphomas.
D'Andrea A; Gritti I; Nicoli P; Giorgio M; Doni M; Conti A; Bianchi V; Casoli L; Sabò A; Mironov A; Beznoussenko GV; Amati B
Oncotarget; 2016 Nov; 7(45):72415-72430. PubMed ID: 27635472
[TBL] [Abstract][Full Text] [Related]
3. Targeting mitochondrial RNA polymerase in acute myeloid leukemia.
Bralha FN; Liyanage SU; Hurren R; Wang X; Son MH; Fung TA; Chingcuanco FB; Tung AY; Andreazza AC; Psarianos P; Schimmer AD; Salmena L; Laposa RR
Oncotarget; 2015 Nov; 6(35):37216-28. PubMed ID: 26484416
[TBL] [Abstract][Full Text] [Related]
4. Tuberous sclerosis complex is required for tumor maintenance in MYC-driven Burkitt's lymphoma.
Hartleben G; Müller C; Krämer A; Schimmel H; Zidek LM; Dornblut C; Winkler R; Eichwald S; Kortman G; Kosan C; Kluiver J; Petersen I; van den Berg A; Wang ZQ; Calkhoven CF
EMBO J; 2018 Nov; 37(21):. PubMed ID: 30237309
[TBL] [Abstract][Full Text] [Related]
5. Vorinostat synergizes with EGFR inhibitors in NSCLC cells by increasing ROS via up-regulation of the major mitochondrial porin VDAC1 and modulation of the c-Myc-NRF2-KEAP1 pathway.
Leone A; Roca MS; Ciardiello C; Terranova-Barberio M; Vitagliano C; Ciliberto G; Mancini R; Di Gennaro E; Bruzzese F; Budillon A
Free Radic Biol Med; 2015 Dec; 89():287-99. PubMed ID: 26409771
[TBL] [Abstract][Full Text] [Related]
6. Could MYC induction of mitochondrial biogenesis be linked to ROS production and genomic instability?
Dang CV; Li F; Lee LA
Cell Cycle; 2005 Nov; 4(11):1465-6. PubMed ID: 16205115
[TBL] [Abstract][Full Text] [Related]
7. Decoding c-Myc networks of cell cycle and apoptosis regulated genes in a transgenic mouse model of papillary lung adenocarcinomas.
Ciribilli Y; Singh P; Spanel R; Inga A; Borlak J
Oncotarget; 2015 Oct; 6(31):31569-92. PubMed ID: 26427040
[TBL] [Abstract][Full Text] [Related]
8. Targeting p300 Addiction in CBP-Deficient Cancers Causes Synthetic Lethality by Apoptotic Cell Death due to Abrogation of MYC Expression.
Ogiwara H; Sasaki M; Mitachi T; Oike T; Higuchi S; Tominaga Y; Kohno T
Cancer Discov; 2016 Apr; 6(4):430-45. PubMed ID: 26603525
[TBL] [Abstract][Full Text] [Related]
9. Inhibition of human mitochondrial peptide deformylase causes apoptosis in c-myc-overexpressing hematopoietic cancers.
Sheth A; Escobar-Alvarez S; Gardner J; Ran L; Heaney ML; Scheinberg DA
Cell Death Dis; 2014 Mar; 5(3):e1152. PubMed ID: 24675470
[TBL] [Abstract][Full Text] [Related]
10. Prevention of tumor formation in a mouse model of Burkitt's lymphoma by 6 weeks of treatment with anti-c-myc DNA phosphorothioate.
Huang Y; Snyder R; Kligshteyn M; Wickstrom E
Mol Med; 1995 Sep; 1(6):647-58. PubMed ID: 8529131
[TBL] [Abstract][Full Text] [Related]
11. Mitochondrial fission factor is a novel Myc-dependent regulator of mitochondrial permeability in cancer.
Seo JH; Agarwal E; Chae YC; Lee YG; Garlick DS; Storaci AM; Ferrero S; Gaudioso G; Gianelli U; Vaira V; Altieri DC
EBioMedicine; 2019 Oct; 48():353-363. PubMed ID: 31542392
[TBL] [Abstract][Full Text] [Related]
12. MYC, Metabolic Synthetic Lethality, and Cancer.
Hsieh AL; Dang CV
Recent Results Cancer Res; 2016; 207():73-91. PubMed ID: 27557535
[TBL] [Abstract][Full Text] [Related]
13. Identification of a locus control region in the immunoglobulin heavy-chain locus that deregulates c-myc expression in plasmacytoma and Burkitt's lymphoma cells.
Madisen L; Groudine M
Genes Dev; 1994 Sep; 8(18):2212-26. PubMed ID: 7958890
[TBL] [Abstract][Full Text] [Related]
14. Human mitochondrial RNA polymerase: structure-function, mechanism and inhibition.
Arnold JJ; Smidansky ED; Moustafa IM; Cameron CE
Biochim Biophys Acta; 2012; 1819(9-10):948-60. PubMed ID: 22551784
[TBL] [Abstract][Full Text] [Related]
15. MYC regulates ribosome biogenesis and mitochondrial gene expression programs through its interaction with host cell factor-1.
Popay TM; Wang J; Adams CM; Howard GC; Codreanu SG; Sherrod SD; McLean JA; Thomas LR; Lorey SL; Machida YJ; Weissmiller AM; Eischen CM; Liu Q; Tansey WP
Elife; 2021 Jan; 10():. PubMed ID: 33416496
[TBL] [Abstract][Full Text] [Related]
16. c-Myc Alteration Determines the Therapeutic Response to FGFR Inhibitors.
Liu H; Ai J; Shen A; Chen Y; Wang X; Peng X; Chen H; Shen Y; Huang M; Ding J; Geng M
Clin Cancer Res; 2017 Feb; 23(4):974-984. PubMed ID: 27401245
[No Abstract] [Full Text] [Related]
17. The c-Myc target gene PRDX3 is required for mitochondrial homeostasis and neoplastic transformation.
Wonsey DR; Zeller KI; Dang CV
Proc Natl Acad Sci U S A; 2002 May; 99(10):6649-54. PubMed ID: 12011429
[TBL] [Abstract][Full Text] [Related]
18. Hyperoxia causes diffuse alveolar damage through mechanisms involving upregulation of c-Myc/Bax and enhanced production of reactive oxygen species.
Shimada I; Kubota A; Katoh M; Suzuki F
Respir Investig; 2016 Jan; 54(1):59-68. PubMed ID: 26718146
[TBL] [Abstract][Full Text] [Related]
19. A Synthetic Lethal Interaction between Glutathione Synthesis and Mitochondrial Reactive Oxygen Species Provides a Tumor-Specific Vulnerability Dependent on STAT3.
Garama DJ; Harris TJ; White CL; Rossello FJ; Abdul-Hay M; Gough DJ; Levy DE
Mol Cell Biol; 2015 Nov; 35(21):3646-56. PubMed ID: 26283727
[TBL] [Abstract][Full Text] [Related]
20. Identification of the mitochondrial protein POLRMT as a potential therapeutic target of prostate cancer.
Li X; Yao L; Wang T; Gu X; Wu Y; Jiang T
Cell Death Dis; 2023 Oct; 14(10):665. PubMed ID: 37816734
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
